Risk, returns & timeframes illustration
1 min read
March 13, 2023
by
Belinda Nash

The fat cats of weight loss 😼

And the Oscar goes to… Ozempic? The slim-down secret is out and TikTok influencers are dancing their way to their doctor for a script. But what is this ‘new’ wave of injectable treatments really designed to treat and how is Oprah weighing in?
1 min read
March 13, 2023
by
Belinda Nash

The fat cats of weight loss 😼

And the Oscar goes to… Ozempic? The slim-down secret is out and TikTok influencers are dancing their way to their doctor for a script. But what is this ‘new’ wave of injectable treatments really designed to treat and how is Oprah weighing in?
1 min read
March 13, 2023
by
Belinda Nash

The fat cats of weight loss 😼

And the Oscar goes to… Ozempic? The slim-down secret is out and TikTok influencers are dancing their way to their doctor for a script. But what is this ‘new’ wave of injectable treatments really designed to treat and how is Oprah weighing in?
Table of contents
Getting Started Investing course
Free Getting Started Course
Take your first, or next, step to becoming a confident investor with Hatch's free online course – just 10 minutes a day, for 10 days.
The Fry up logo with fried egg
Weekly news from Wall St
Subscribe to The Fry Up - your weekly sizzle of headline-grabbing share market news. Read by 60,000 Kiwis to help them take charge of their investing journey.

The celebrity weight loss biohack roasted by Oscar host Jimmy Kimmel, shared by Elon Musk, denied by the Kardashians 🙅♀️ and plumping up on TikTok may have triggered global shortages of some popular injectable drugs, but is there any fat to the fat-zapping fad? 

In 2005, AstraZeneca (AZN) was the first to gain approval for a type 2 diabetes treatment to lower blood sugar levels and suppress appetite with a glucagon-like peptide-1 receptor agonist (GLP-1) injection, called Byetta. 💉 They’ve since released Bydureon and Bydureon BCise, and today Big Pharma has bulked up in the fight against diabetes. Eli Lilly (LLY) produces injectables Trulicity and Mounjaro, and Novo Nordisk (NVO - ADR) makes Ozempic, Wegovy, Saxenda and Victoza, and oral pill, Rybelsus, all brand names for semaglutide, tirzepatide, liraglutide, exenatide and dulaglutide. 💊

But it’s the weight loss effect of these incretin hormone drugs - with users losing up to 15-20% of their body weight - that has TikTokers dancing. 💃

Scientific modelling projects that nearly 14% of the US population could have diabetes by 2030, and 18% by 2060 - currently that number is 10.5% in the US and around 5% in Aotearoa. So it’s unlikely the GLP-1 drug category will slim down anytime soon. Even Oprah’s purse could get rotund. 👛 The queen of all media owns a slice of Weight Watchers (WW), which last week announced they’re scaling up, with plans to acquire telehealth prescription drug company, Sequence, briefly bloating WW’s stock 50%. Could a future WW consult come with a side of Ozempic? 🍽️

As the slim-fad helps fatten drugmakers, investors have seen the bulge hit their portfolios. Since the trend started gaining weight, from January 2021, AstraZeneca’s stock has piled on the pounds 28%, Eli Lilly’s has padded out 95%, and Novo Nordisk’s stock has beefed up a hefty 100%. And with the feast of diet drugs like Ozempic costing between US$200 and US$$1,300 per month, coupon clipping may have never looked so good! ✂️

Belinda Nash
Finance writer
Linkedin

We’re not financial advisors and Hatch news is for your information only. However dazzling our writing, none of it is a recommendation to invest in any of the companies or funds mentioned. If you want support before making any investment decisions, consider seeking financial advice from a licensed provider. We’ve done our best to ensure all information is current when we pushed ‘publish’ on this article. And of course, with investing, your money isn’t guaranteed to grow and there’s always a risk you might lose money.

Join the Kiwis who are hatching their tomorrow and have invested more than $1 billion with Hatch.

Explore another series
Tax
Money
Economy
Investing

More recent news articles

Recent learn articles

7 min read
May 7, 2024

Street-fighter mode: McDonald’s supersizing burgers to win back frugal customers

McDonald’s CEO Chris Kempczinski says they’re feeling the loss of low earning customers during the high cost of living, promising to bring back value dining, as well as creating their biggest burger ever. But one financial analyst has dug into the data, and he tells a different story.
Read more
7 min read
Apr 16, 2024

Geopolitical pressures wobble big bank’s outlook

Big banks have kicked off quarterly earnings season in the US markets, but JPMorgan CEO Jamie Dimon’s sobering shareholder letter sent the bank stocks tumbling sector-wide last week. But there is still investor optimism in the global financial powerhouses, with stock soars in the past six months that even rival some Big Tech.
Read more
8 min read
Apr 9, 2024

Disney survived a hostile takeover, what have we learned?

Disney beat Nelson Peltz in his battle for boardroom control, ending years of struggles that kicked off during Covid. Retired CEO Bob Iger returned to bring the legacy entertainer back from big losses, but he can’t stay forever. So what happened behind closed doors during the failed hostile takeover?
Read more

Related news articles

More recent learn articles

No items found.

Recent news articles

More recent learn articles

7 min read
May 7, 2024

Street-fighter mode: McDonald’s supersizing burgers to win back frugal customers

McDonald’s CEO Chris Kempczinski says they’re feeling the loss of low earning customers during the high cost of living, promising to bring back value dining, as well as creating their biggest burger ever. But one financial analyst has dug into the data, and he tells a different story.
Read more
7 min read
Apr 16, 2024

Geopolitical pressures wobble big bank’s outlook

Big banks have kicked off quarterly earnings season in the US markets, but JPMorgan CEO Jamie Dimon’s sobering shareholder letter sent the bank stocks tumbling sector-wide last week. But there is still investor optimism in the global financial powerhouses, with stock soars in the past six months that even rival some Big Tech.
Read more
8 min read
Apr 9, 2024

Disney survived a hostile takeover, what have we learned?

Disney beat Nelson Peltz in his battle for boardroom control, ending years of struggles that kicked off during Covid. Retired CEO Bob Iger returned to bring the legacy entertainer back from big losses, but he can’t stay forever. So what happened behind closed doors during the failed hostile takeover?
Read more